Danegaptide

• Description:

  Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect[1][2].

• Product Name Alternative:

  GAP-134; ZP 1609

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Gap Junction Protein

• Type:

  Reference compound

• Related Pathways:

  Cytoskeleton

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/gap-134.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@H]1CN(C(CN)=O)[C@H](C(O)=O)C1)C2=CC=CC=C2

• Molecular Formula:

  C14H17N3O4

• Molecular Weight:

  291.30

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]John A Butera, et al. Discovery of (2S,4R) -1- (2-aminoacetyl) -4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134) 13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation. J Med Chem. 2009 Feb 26;52 (4) :908-11.|[2]Elke De Vuyst, et al. Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. Br J Pharmacol. 2011 Jun;163 (3) :469-83.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [943134-39-2]